2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10627
    SOD1 (147-153) human 2760733-01-3 98%
    SOD1 (147-153) human is a peptide fragment of Cu/Zn superoxide dismutase (SOD1) with a high propensity to form amyloid fibrils. SOD1 (147-153) human may trigger the aggregation of full-length SOD1 and is a common molecular determinant of familial amyotrophic lateral sclerosis (fALS) and sporadic amyotrophic lateral sclerosis (sALS).
    SOD1 (147-153) human
  • HY-P10628
    β Amyloid (1-14), human 98%
    β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research.
    β Amyloid (1-14), human
  • HY-P10630
    Pep63 1781242-18-9 98%
    Pep63 is a neuroprotective peptide (VFQVRARTVA). Pep63 has a neuroprotective effect on synaptic plasticity and memory. Pep63 can competitively bind with Aβ1-42 oligomers, and can block Aβ fiber formation. Pep63 can be used for Alzheimer’s disease (AD) research.
    Pep63
  • HY-P10674
    QMT-CBT 98%
    QMT-CBT is a near-infrared aggregation-induced luminescent photon. After activation of caspase1 (Cas1), QMT-CBT undergoes a CBT-Cys click reaction to form a cyclic dimer QMT-Dimer (the first aggregate) and assembles into nanoparticles (the second aggregate), turning the AIE signal "on" to enhance imaging of Alzheimer's disease (AD).
    QMT-CBT
  • HY-P10690
    CCHa1 peptide 98%
    CCHa1 peptide is a signaling peptide that plays a role in inhibiting sleep arousal. It is produced by enteroendocrine cells in the gut and modulates the animal's response to sensory inputs such as mechanical vibrations by acting on specific dopamine neurons in the brain, thereby helping to suppress arousal responses. CCHa1 peptide holds potential for research in fields related to sleep quality and sensory adaptation.
    CCHa1 peptide
  • HY-P10698
    VH-N412 1801681-81-1 98%
    VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.
    VH-N412
  • HY-P10737
    CGGK 1253739-14-8 98%
    CGGK is a control peptide of CAQK peptide (HY-P10216).
    CGGK
  • HY-P1075A
    CALP3 TFA 98%
    CALP3 TFA, a Ca2+-like peptide, is a potent Ca2+ channel blocker that activates EF hand motifs of Ca2+-binding proteins. CALP3 TFA can functionally mimic increased [Ca2+]i by modulating the activity of Calmodulin (CaM), Ca2+ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia.
    CALP3 TFA
  • HY-P10767
    MD01-67 2468971-42-6 98%
    MD01-67 is a selective macrocyclic compound targeting the neurotensin receptor type 2 (NTS2), with Ki of 2.9 nM. MD01-67 exhibits analgesic and tactile hypersensitivity reducing activity in rats acute/persistent/chronic inflammatory pain models.
    MD01-67
  • HY-P10778
    me4 Peptide 98%
    me4 Peptide is a synthetic peptide designed based on the microexon me4 sequence of neuronal CPEB4 protein. me4 Peptide inhibits CPEB4 aggregation. me4 Peptide can be used in the study of disorders associated with autism spectrum disorders.
    me4 Peptide
  • HY-P1078A
    Huwentoxin XVI TFA 98%
    Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels.
    Huwentoxin XVI TFA
  • HY-P10799
    SLAFVDVLN 98%
    SLAFVDVLN, a molecular peptide, is a BACE-1 inhibitor with a Ki value of 94 nM. SLAFVDVLN can reduce Aβ42 production.
    SLAFVDVLN
  • HY-P10811
    Na+-Ca2+ Exchanger 98%
    Na+-Ca2+ Exchanger inhibitory peptide (XIP) is a Na+-Ca2+ exchanger inhibitor with a Ki of 200 nM. Na+-Ca2+ Exchanger inhibitory peptide inhibits the Na+-dependent Ca2+ uptake and the Na+-dependent Ca2+ efflux of sarcolemmal vesicles in a noncompetitive manner.
    Na+-Ca2+ Exchanger
  • HY-P10822
    ED11 1593480-56-8 98%
    ED11 is a potent and selective caspase-6 inhibitor with an IC50 of 12.12 nM. ED11 competes with Htt for the caspase-6 active site, and thus reduce Htt cleavage. ED11 can cross the blood-brain barrier (BBB). ED11 has the potential for the study of Huntington's disease (HD).
    ED11
  • HY-P10823
    RI-OR2 1219627-58-3 98%
    RI-OR2, a retro-inverso peptide, is an amyloid-β (Aβ) oligomerization inhibitor. RI-OR2 binds to immobilized β-Amyloid (1-42) (HY-P1363A) monomers and fibrils, with an apparent Kd of 9-12 μM, and also acted as an inhibitor of Aβ(1-42) fibril extension.
    RI-OR2
  • HY-P1083A
    Dynamin inhibitory peptide TFA 98%
    Dynamin inhibitory peptide TFA competitively blocks binding of dynamin to amphiphysin, thus preventing endocytosis. Dynamin inhibitory peptide TFA blocks the dopamine D3 effect on GABAA receptors.
    Dynamin inhibitory peptide TFA
  • HY-P1084A
    β-Pompilidotoxin TFA 98%
    β-Pompilidotoxin TFA (β-PMTX TFA), a wasp venom, can slow sodium channel inactivation and increases steady-state sodium current in cells.
    β-Pompilidotoxin TFA
  • HY-P10854
    TAT-N15 2415370-74-8 98%
    TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke.
    TAT-N15
  • HY-P10861
    RI-AG03 98%
    RI-AG03 is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 can be used for research on tau-related diseases such as Alzheimer's disease.
    RI-AG03
  • HY-P10876
    mcK6A1 98%
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases.
    mcK6A1
Cat. No. Product Name / Synonyms Application Reactivity